A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Condition(s) studied

Investigational drug(s) / intervention(s)

Siltartoxatug Injection (Brand name: Sintetol®): The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Study summary

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Eligibility

Primary outcome measure(s)

• Primary Outcome — within 90 days
  Tetanus protection rate within 90 days post-administration of Siltartoxatug Injection (calculated as 1- tetanus incidence rate)

Trial sites (4)

More Zhuhai Trinomab Pharmaceutical Co., Ltd. trials in China

Other trials for the same condition